French researchers question biologic trial designs
The care given to patients in control groups of many biologic trials is often inferior to the normal standard of care, a virtual study shows.
French researchers asked rheumatologists to rate whether 30 protocols would be suitable treatments for 90 patients with RA described in case vignettes. Unbeknownst to the physicians, the protocols had been taken from the control arms of biologic RCTs.
For 45% of